Search clinical trials for: afatinib

Total 2166 results

Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Baise and other collaborators

Unknown

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Wan-Guang Zhang

Recruiting

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC (CCGLC-010)

Macrotrabecular Massive Hepatocellular Carcinoma

China
Zhengzhou University

Unknown

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Newly Diagnosed Peripheral T-cell Lymphoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Elevar Therapeutics

Completed

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Cancer

United States
National Nutrition and Food Technology Institute

Unknown

The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

Non Alcoholic Steatohepatitis

Iran, Islamic Republic of
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer
Binkui Li

Recruiting

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Yunfei Yuan

Recruiting

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Hebei Medical University

Unknown

Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Gastroesophageal Junction Adenocarcinoma

China
The Second Hospital of Hebei Medical University

Unknown

TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT

Glioma

China
Peking University Cancer Hospital & Institute

Unknown

A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST

Gastrointestinal Stromal Tumor

China
GlaxoSmithKline

Completed

GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Colorectal Cancer

United States, Canada
Kanto CML Study Group

Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase

Japan
GlaxoSmithKline

Terminated

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Neoplasms, Breast

Italy, United Kingdom
Poitiers University Hospital
Novartis; Roche Pharma AG; Ministry of Health, France

Completed

STI571 ProspectIve RandomIzed Trial: SPIRIT (SPIRIT)

Chronic Myeloid Leukemia

France
R-Pharm
GlaxoSmithKline

Terminated

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Locally Advanced or Metastatic Breast Cancer

United States, Italy, Australia
Georgetown University
GlaxoSmithKline

Completed

Lapatinib and Cetuximab in Patients With Solid Tumors (TYKERB-ITUX 1)

Head and Neck Cancer | Colorectal Cancer | Lung Cancer

United States
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic

United States
Huashan Hospital
Boehringer Ingelheim

Not yet recruiting

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Chordoma of Clivus

China
Shanghai Pulmonary Hospital, Shanghai, China

Completed

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III

China
Boehringer Ingelheim

Completed

Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy (LUX-Bladder 1)

Urologic Neoplasms

Spain, France, Italy
Boehringer Ingelheim

Completed

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Boehringer Ingelheim

Completed

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Carcinoma, Non-Small-Cell Lung

Hong Kong, China, Taiwan, Singapore, India
Affiliated Hospital of Hebei University

Unknown

A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases

Non-squamous Non-small Cell Lung Cancer

China
Jiangsu ShengDiYa Medicine Co., Ltd.
Dongguan People's Hospital

Unknown

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Nonsquamous Nonsmall Cell Neoplasm of Lung
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium

Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia

United States
University Hospital, Angers

Completed

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia (DasaCBF)

Acute Myelogenous Leukemia

France
CytRx

Completed

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

B-Cell Chronic Lymphocytic Leukemia

United States
Pfizer

Completed

Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Carcinoma, Non-small Cell Lung

United States, Germany
University of Alabama at Birmingham
GlaxoSmithKline

Terminated

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Ovarian Cancer

United States
Benazir Bhutto Hospital, Rawalpindi

Completed

Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics

Acute Pancreatitis

Pakistan
Pfizer

Completed

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Carcinoma, Renal Cell

United States, Spain, Japan, Germany, Czechia, Russian Federation
Chinese University of Hong Kong

Completed

Nasopharyngeal Carcinoma (NPC) Axitinib

Recurrent or Metastatic NPC

Hong Kong
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
National University Hospital, Singapore

Not yet recruiting

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Squamous Cell Carcinoma

Singapore
Peking University

Unknown

Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Esophageal Squamous Cell Carcinoma

China
Fujian Cancer Hospital

Unknown

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma
Universitätsmedizin Mannheim

Completed

Predictors for Bronchoalveolar Lavage (BAL) Recovery Rate Derived From Quantified Computed Tomography (qCT)

Pneumonia | Interstitial Lung Disease | Malignant Neoplasm
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada
National Taiwan University Hospital

Unknown

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Triple Negative Breast Cancer

Taiwan
Massachusetts General Hospital
National Comprehensive Cancer Network

Unknown

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Non Small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Approved for marketing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Boehringer Ingelheim

Terminated

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex (THEN)

SMALL CELL LUNG CARCINOMA

France
Cancer Institute and Hospital, Chinese Academy...

Completed

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Breast Cancer

China

3

Subscribe